

# Is the myonuclear domain size fixed?

S.F.T. Van der Meer<sup>1,2,\*</sup>, R.T. Jaspers<sup>3</sup>, H. Degens<sup>1,2</sup>

<sup>1</sup>Institute for Biomedical Research into Human Movement and Health, Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester M1 5GD, United Kingdom; <sup>2</sup>Institute of Aerospace Medicine, Division Space Physiology, German Aerospace Center, Cologne, Germany;

<sup>3</sup>Research Institute MOVE, Faculty of Human Movement Sciences, VU University Amsterdam, Amsterdam, The Netherlands

\* deceased 28 July 2010

## Abstract

It has been suggested that the number of myonuclei in a muscle fibre changes in proportion to the change in fibre size, resulting in a constant myonuclear domain size, defined as the cytoplasmic volume per myonucleus. The myonuclear domain size varies, however, between fibre types and is inversely related with the oxidative capacity of a fibre. Overall, the observations of an increase in myonuclear domain size during both maturational growth and overload-induced hypertrophy, and the decrease in myonuclear domain size during disuse- and ageing-associated muscle atrophy suggest that the concept of a constant myonuclear domain size needs to be treated cautiously. It also suggests that only when the myonuclear domain size exceeds a certain threshold during growth or overload-induced hypertrophy acquisition of new myonuclei is required for further fibre hypertrophy.

**Keywords:** Skeletal Muscle, Myonuclear Domain, Satellite Cell, Hypertrophy, Atrophy, Ageing, Growth

## Introduction

Skeletal muscle has a remarkable ability to respond to altered functional demands. During disuse, for instance, the muscle atrophies, while in response to overload the muscle hypertrophies. Whatever the condition that causes muscle fibre atrophy or hypertrophy, the speed and magnitude of this change in size are the result of an altered balance between protein synthesis and degradation. Although protein synthesis and degradation are regulated by different sets of complex independent pathways, there are indications of some interaction between the two, where specific proteins that stimulate protein synthesis also inhibit the expression of proteins that increase the activity of protein degradation pathways<sup>1,2</sup>. Protein degradation is executed by the interaction of several different proteolytic pathways: 1) the cytosolic calcium-dependent calpain system, 2) the lysosomal proteases, 3) the ATP-dependent

ubiquitin proteasome system<sup>2-4</sup> and 4) caspases<sup>5</sup>. The rate of protein synthesis can be regulated by: 1) the rate of protein translation, 2) the amount of available mRNA and 3) the transcriptional capacity.

The translational capacity is determined by the number and translational efficiency of ribosomes<sup>6</sup>. Given that the fraction of ribosomal RNA accounts for approximately 80-85% of the total cellular RNA pool<sup>7</sup>, changes in the total RNA concentration are generally regarded to reflect a change in the translational capacity<sup>6</sup>. The transcriptional capacity is determined, at least partly, by the amount of available nuclear DNA. While most cell types (e.g. neuronal cells, macrophages, fibroblasts, lymphocytes, osteocytes) in mammals are mono-nucleated, muscle fibres contain multiple nuclei (Figure 1). Single soleus muscle fibres from 5-month-old rats, for instance, contain approximately 300 myonuclei per mm muscle fibre length<sup>8</sup>. Those nuclei originate from the fusion of multiple myoblasts into one myotube<sup>9</sup> during embryonic development. Muscle nuclei, further indicated as myonuclei, have a flattened and elongated shape and their length varies between 11-25  $\mu\text{m}$  e.g.<sup>10,11-15</sup> and does not vary significantly with age and denervation-induced atrophy (Figure 2)<sup>14</sup>.


For more than a century scientists have had the idea that each nucleus has a 'Wirkungskreis' or 'volume of influence'<sup>16</sup>. The general belief was that nuclear size was related to cytoplasmic volume. In other words, it was thought that the size of mononuclear cells was largely determined by the size of the

The authors have no conflict of interest.

Corresponding author: Dr. ir. Hans Degens, Institute for Biomedical Research into Human Movement and Health, Manchester Metropolitan University, John Dalton Building; Chester Street, Manchester M1 5GD; United Kingdom  
E-mail: h.degens@mmu.ac.uk

Edited by: F. Rauch


Accepted 20 November 2011



**Figure 1.** Fragment of a single human vastus lateralis muscle fibre showing in blue the myonuclei.

myonucleus<sup>17</sup>. Only in the 1960s scientists became interested in the relationship between cell size and number of nuclei in skeletal muscle<sup>18-20</sup>. It was, however, Cheek and colleagues who in 1971 hypothesised that ‘each nucleus held jurisdiction over a finite volume of cytoplasm’ and developed the concept of a ‘DNA unit’<sup>20</sup>. A functional DNA unit was defined as the content of non-collagen-protein per DNA content. It should be noted, however, that by measuring the DNA content in a muscle homogenate also nuclei originating from other cell types (satellite cells, fibroblasts, endothelial cells etc.) are included. A more accurate assessment of the relationship between number of nuclei and the muscle fibre size would be based on a count of the myonuclei in a muscle fibre.

Landing and colleagues, using single muscle fibres, showed for the first time that the distribution of the nuclei in muscle fibres follows regular patterns; each nucleus was surrounded by six other nuclei in an “elongated hexagon” further supporting the idea that each myonucleus has a “surface territory” as indicated by the “cytoplasmic-volume-to-nucleus ratio”<sup>21</sup>. Edgerton and Roy<sup>22</sup> pointed out that a myonucleus can theoretically act in two scenarios as illustrated in Figure 3. According to the model represented in Figure 3A and described by Cheek<sup>20</sup> and Hall and Ralston<sup>23</sup> a myonucleus provides all transcripts for a given volume of cytoplasm in its direct surrounding. In the model of Figure 3B each myonucleus expresses only specific proteins, but does so for the whole muscle fibre. Many observations support the first concept. Some proteins are not homogeneously expressed over the full length of the muscle fibre<sup>24</sup>. In addition, considering the limited half-life of mRNA and relatively large dimensions of a muscle fibre (they can be several cm long and up to 0.2 mm in diameter), it seems unlikely that muscle fibres could maintain their size if transcripts must diffuse over long distances within the fibre<sup>22</sup>. Indeed mRNA does not range far from its nucleus of origin<sup>25,26</sup>. Besides, the concept of a myonuclear domain can only be useful when one assumes that each myonucleus has a certain spa-



**Figure 2.** Myonuclear length determined in single isolated fibres from young-adult control (Y-C), young-adult 4-week denervated (Y-DNV), old control (O-C) and old 4-week denervated (O-DNV) rat gastrocnemius muscles (3 fibres from 3-4 muscles in each group). Myonuclear length (in  $\mu\text{m}$ ) was estimated as the longest length of a best-fit ellipse. The angle of each myonucleus was corrected for the angle at which the muscle fibre fragment was captured. In three different regions of the fibre the mean sarcomere length was determined to correct nuclear length for sarcomere length (hence the y-axis presents myonuclear length normalized for sarcomere length which was in all cases close to  $2.4 \mu\text{m}$ ) and orientation of the nucleus within the fibre. Each data point represents the mean of  $21 \pm 3.4$  (mean  $\pm$  SEM) myonuclei. Using a two-way ANOVA, it appeared that age and denervation did not have a significant effect on myonuclear length (unpublished observations).


tial limitation to control its surrounding cytoplasm<sup>22</sup>.

Further support for the concept that each myonucleus has a limited cytoplasmic volume which it can supply is the observation that under normal physiological conditions the number of myonuclei per muscle fibre is proportionally positively related to muscle fibre size in both animal<sup>15,27-29</sup> and human muscle<sup>30,31</sup>. If this concept of a constant myonuclear domain size is true, then any change in the size of a fibre will be accompanied by a proportional change in the number of myonuclei in that fibre: the possible scenarios are illustrated in Figure 4B-E.


In this review we will explore the validity of this concept by looking at reported changes in myonuclear domain size during maturational growth, hypertrophy, atrophy and ageing.

## The myonuclear domain in fibres of different type

The myonuclear domain size appears to differ between fibre types, where it increases from type I to IIA to type IIB/X fibres<sup>14,29</sup>. In rat gastrocnemius muscle the larger myonuclear domain size in the type IIA than type I fibres was due to a lower number of myonuclei, and not a larger size of the IIA fibres. In contrast, in type IIB/X fibres the number of myonuclei in the fibre was similar to that of type I fibres but type



**Figure 3.** Two concepts of myonuclear domain. The arrows indicate the domain of cytoplasm that the myonuclei supply with mRNA transcripts. In the left diagram (A) the myonucleus provides the cytoplasm in its direct surrounding of transcripts, whereas in the right diagram (B) it is assumed that each nucleus produces only specific transcripts which diffuse through the whole muscle fibre.



**Figure 4.** Possible scenarios of changes in myonuclear domain size with different types of muscular adaptation.

IIB/X fibres had a larger fibre cross-sectional area (FCSA)<sup>14</sup>. These differences in myonuclear domain size between fibre types could well be related to the higher oxidative capacity of the type I and IIA than the type IIB/X fibres since the myonu-

clear domain size is inversely related to the oxidative capacity of the fibre<sup>15,32</sup>. Further support for the notion that the myonuclear domain size is related to the oxidative capacity of muscle fibres rather than the myosin heavy chain type of the fibre is

provided by the observation that the type II fibres in the superficial glycolytic region of the rat plantaris muscle with a relatively low oxidative capacity had a larger myonuclear domain than type II fibres in the deep oxidative region of the plantaris muscle with a high oxidative capacity<sup>33</sup>. A possible explanation for the differences in myonuclear domain size between fibres of different types may be that oxidative fibres have a faster protein turnover and hence a higher demand for mRNA transcription, also of mitochondrial proteins. It has indeed been observed that protein turnover rate is higher in slow than in fast muscles<sup>2,34</sup>. Overall, it signifies that the myonuclear domain size is not fixed but does vary between fibre types and with the oxidative capacity of the fibre.

### Myonuclear domain and increases in muscle size

Skeletal muscle growth is largely, if not solely, attributable to an increase in fibre size. According to the concept of the myonuclear domain this should be associated with a proportional increase in the number of myonuclei to maintain the myonuclear domain size. Below we will discuss what happens during maturational growth of the muscle and exercise- or overload-induced muscle growth or hypertrophy.

An increase in the number of myonuclei is realised by the fusion of satellite cells with the existing muscle fibre(s). Satellite cells were discovered by Mauro<sup>35</sup> who named them after their location between the plasma membrane of the muscle fibre and the basement membrane (also referred to as 'basal lamina') that surrounds the muscle fibre. Once activated the expression of the myogenic regulatory factor MyoD is increased and the cell starts to divide. During this proliferation phase the expression of the myogenic regulatory factors will shift from MyoD to myogenin, which is thought to be crucial for satellite cell differentiation. At fusion with the muscle fibre, the satellite-cell nucleus is donated to the existing muscle fibre and will function as a myonucleus. It should be noted, however, that not all activated satellite cells differentiate into a myonucleus. After proliferation some satellite cells are withdrawn from the differentiation process<sup>36</sup>. It is hypothesised that those satellite cells fall back to a quiescent state and maintain a pool of satellite cells that can be activated during later repair, regeneration or hypertrophy<sup>36</sup>.

#### *Maturational muscle growth*

During maturational growth, the lengthening of the bones is tightly associated with increases in skeletal muscle volume. An expansion of muscle volume can be achieved by increases in the number, length and/or cross-sectional area (FCSA) of the muscle fibres. Since it is generally believed that the number of muscle fibres is set at around the first months after birth<sup>37,38</sup>, the increase in muscle volume during growth must be the result of an up to 23-fold increase in fibre size<sup>39-41</sup> and an increase in muscle fibre length<sup>42,43</sup>.

In 1964 Enesco and Puddy reported that the number of myonuclei increased during the first three months of growth in rats, but did not formulate any hypotheses on the relevance of

a possible coupling between the cell size and the number of nuclei<sup>44</sup>. In the pectoralis and gastrocnemius muscles from growing chickens a logarithmic relationship was observed between the number of nuclei, estimated by the DNA content, and the muscle fibre diameter<sup>18,19</sup>. They relied thereby on earlier findings that the DNA-per-nucleus ratio in various mammalian cells was a constant value of about 6.2 pg per nucleus<sup>20</sup>. In the early reports of nuclear increases during muscle growth<sup>18,44</sup> myonuclei were not discriminated from other nuclei. Although Enesco and Puddy demonstrated that the fraction of muscle nuclei, nuclei that were considered inside a muscle fibre, remained fairly stable (60-70%) in each of four different rat muscles during their development from 16 to 89 days, those reports should be interpreted with some caution.

Nevertheless, these early studies were subsequently confirmed by additional observations of a substantial increase in the number of myonuclei per muscle fibre during the early weeks and months of growth in rodents<sup>8,42,45,46</sup>. However, the increase in myonuclear number was shown to be less than the increase in FCSA and consequently the myonuclear domain size expands during growth. The expansion of the myonuclear domain size during maturational growth in rat diaphragm muscle fibres was more pronounced in type IIX than in IIA or type I muscle fibres<sup>46</sup>. This suggests that, at least in rat, the growth of type IIX fibres requires a smaller transcriptional capacity than is the case for the type I and IIA muscle fibres and corresponds with a lower protein turnover rate in fast than slow fibres<sup>2,34</sup>, requiring a lower transcriptional activity.

Little is known about changes in myonuclear number during growth in human muscle, but the few data available suggest that the pattern observed in rodents and chicken also applies to human muscle. Muscles of children in the age of 1-2.5 years old contained approximately half the number of myonuclei per muscle fibre of those from adult muscles (12-30 years old)<sup>41</sup>. At first glance the proportional increase in myonuclei and myofibre diameter suggests that the nuclear domain size remains constant. However, FCSA increases quadratically with diameter and hence it is clear that also in this case there is an increase in the myonuclear domain size during growth. It is unclear, however, what happens in the first few months after birth. As the number of satellite cells declined rapidly during the first weeks of growth of rat skeletal muscles<sup>12,42,47,48</sup>, it is no surprise that myonuclear accretion slows down during maturation<sup>42</sup>.

Overall the changes in FCSA and nuclear number during growth resemble the situation depicted in Figure 4C where the nuclear domain size is not constant but rather increases during maturational muscle growth. It thus seems that the concept of a constant nuclear domain size needs to be abandoned at least during maturational muscle growth. Maturational growth is a special situation where the whole body, including the muscle, is geared to subsequent growth. This requires an exceptional transcriptional activity which is undoubtedly much higher than one would see in the adult myofibre that finds itself in a more or less steady state. It is interesting to note, however, that the increase in myonuclear domain size as a consequence of a larger increase in FCSA than nuclear number much resembles the larger in-



Reference	Species	Age	Model	Duration (days, months)	N	Muscle	change MN (%)	change FCSA (%)	change MD (%)
29	R-SD♀	180 g	Overload	10 weeks	3	PL	61-109	36-90	=
33	R-W♂	5 mo	Overload	28 days	5	PL	↑	33	=
		25 mo			3		↑	33	=
51	R-SD♀	212 g	Overload	90 days	6	PL	44	46	=
			Overload+IR		6		=	=	=
56	R-W♂	152 g	Overload	28 days	6	EDL	ND	21 (ww)	=
			Overload+IR		6			-24 (ww)	19
57	R-W♂	4-5 mo	Overload	28 days	8	EDL	ND	18 (ww)	=
		(450-500 g)	Overload IR		8			= (ww)	=
54	H♀	28	RT	16 weeks	13	VL	=	27	17
		63			13		=	17	16
54	H♂	26	RT	16 weeks	13	VL	19	27	10
		65			13		=	17	10
59	H♂	24	RT	90 days	15	VL	=	17	17*

*H: Human; R: Rat; ♀: Female; ♂: Male; W: rat strain Wistar; SD: rat strain Sprague-Dawley; Age in years for human and in mo (months) for rats; (N): number of participants / animals; MN: myonuclear number; FCSA: fibre cross-sectional area; MD: myonuclear domain; ww: % change in wet weight; Muscles: VL: vastus lateralis; PL: Plantaris; EDL: Extensor digitorum longus; IR: irradiation; All changes have been expressed as change in hypertrophied compared to control muscles; =: no significant change with hypertrophy; \*:change estimated from authors graph.*

**Table 1.** Studies investigating the effect of hypertrophy on the myonuclear domain size.

crease in FCSA than capillary number during growth, resulting in an increased capillary supply or ‘capillary domain’ area<sup>39</sup>. Also in that case, like the number of myonuclei<sup>41</sup>, the capillary number per fibre radius remained constant<sup>39</sup> suggesting that the average distance between myonuclei remains relatively constant during growth. The significance of this distribution of myonuclei is something for further exploration.

### Hypertrophy

It is a point of discussion whether or not the acquisition of new myonuclei is required for skeletal muscle hypertrophy<sup>49,50</sup>. Table 1 gives an overview of the changes in myonuclear domain size during hypertrophy. At a first glance, the increase in the myonuclear number during hypertrophy in animals<sup>29,33,51-53</sup> and young-adult men<sup>54</sup> appears to support the notion of a constant myonuclear domain size. The importance of myonuclear addition for muscle fibre hypertrophy is further supported by the attenuated<sup>55,56</sup> or even prevented hypertrophy after ‘gamma-irradiation’<sup>51,57,58</sup>, which destroys the potential of mitotic division in various cell types, including the satellite cells. However, it has been shown that hypertrophy to some extent is possible without any change in the number of myonuclei<sup>33,54,59,60</sup>. Using a cluster-analysis of a 4-months resistance training program in humans, it was observed that participants who responded with only moderate ( $9.7 \pm 2.4\%$ ) hypertrophy were those where the number of myonuclei per muscle fibre did not increase and the myonuclear domain size remained below  $2,000 \mu\text{m}^2$ <sup>54</sup>. This value was proposed as a ‘ceiling’ of the myonuclear domain size beyond which additional hypertrophy can only be realised by addition of new myonuclei<sup>54</sup>. The proposed values of a hy-

pertrophy threshold or a ceiling of the myonuclear domain size are somewhat arbitrary. In this perspective it is interesting to note that recently for a variety of species it has been shown that myonuclear domain size scales in proportion to body mass<sup>61</sup>. Thus, a myonuclear domain size ceiling or hypertrophy threshold may vary between species.

There is, however, a lack of knowledge regarding the time course of changes in the number of myonuclei during hypertrophy<sup>62</sup>. In one such study significant hypertrophy of the plantaris muscle was attained after 2 weeks of overload without a concomitant increase in myonuclear number<sup>33</sup>. Consequently, the myonuclear domain size increased and only after 4 weeks of overload did the number of myonuclei increase<sup>33</sup>. This observation corresponds with the notion of a ceiling of hypertrophy where further hypertrophy after 2 weeks of overload requires the addition of new myonuclei. A recent study casts some doubt on this conclusion as they found a stunning doubling in muscle size after only two weeks of overload in satellite cell depleted mice<sup>63</sup>. Although one could argue that the muscle fibres would be of lower functional capacity the authors reported normal single muscle fibre function. Apparently the myonuclei do have a reserve capacity. The acquisition of new myonuclei does take time and requires proliferation of satellite cells, that can be detected as early as 1 week after induction of overload<sup>58</sup>, and subsequent differentiation into a myonucleus. This may only result in a significant increase in the number of myonuclei after more than 2 weeks of overload<sup>33</sup>, emphasising the need for a reserve capacity of the myonuclei to cope with sudden changes in demand for mRNA transcripts. It is thus possible that doubling in muscle size within two weeks in satellite

Reference	Species	Age (months)	Model	Duration (days, months)	N	Muscle	change MN (%)	change FCSA (%)	change MD (%)
<b>Bed rest</b>									
101	H, ♂	31 yrs	B	2 mo 4 mo	6 6	VL	= =	= -35	= -35*
<b>Denervation</b>									
74	R-SD, ♂	adult	DNV	14 d	5	Diaph, I Diaph, IIA Diaph, IIX Diaph, IIB	= = = =	+15 = -46 -67	+26 = -51 -69
75	M <sup>1</sup>	4	DNV	10 d 4 mo	-	PL	= =	-43* -58*	-43* -54*
11	R-W, ♂	1.5	DNV	2.5 mo	~7 fibres	EDL	-17 <sup>2</sup>	-95	-
102	R-W, ♀	170-200 g	DNV	7 d		SM	=	-	-37
103	M-NMRI, ♀		- DNV	14 d		EDL	=	-	-60
				7 d			=	=	-
				14 d			=	-29*	
				21 d		SOL	=	-51	
				14 d			=	-42*	
104	R-WI/Hick, ♂	4	DNV	21 d	3	EDL	=	-55	
				20 mo			-36	-86*	-88
				4 mo	3		-53	-97*	-96
				7 mo	3		-68	-98*	-92
11	R-W, ♂	1.5	DNV	2.5mo		SOL	-60	-99	-
14	R-W, ♂	5	DNV	7 d	5	Gast	=	-47	- ca 45
<b>Spinal cord injury</b>									
71	R-SD, ♀	adult	SI	4 d 2 mo	5 5	SOL, I	= -25	-41 -66	-36 -55
68	R-SD, ♀	adult	SI	10 d	4-5	SOL	-25	-	-
53	C, ♀	adult	SI	6 mo	3	SOL, I SOL, II	= -32	-66 -74	-64 -60
<b>Hindlimb suspension</b>									
97	R-F344.BN, ♂	6	HLS	7 d 14 d	6 6	SOL	= -36*	-24 -62	= -41*
52	R-W, ♂	3	HLS	14 d	8	SOL	-31	-50	-28
73	R-W, ♀	3	HLS	14 d	4	SOL, I SOL, II PL, I PL, II	+20 +15 = =	-55 -44 = -29	-63 -44 = -40
105	R, F344.BN, ♂	6	HLS	14 d	6	SOL	-37*	-72	-42*
72	R-SD, ♀	3	HLS	14 d	4	SOL	-17	-55	-45
106	M-C57BL/6J, ♂	2	HLS	14 d 28 d 42 d 56 d	?   	SOL	= = = =	-40 <sup>ww</sup> = = =	-   
<b>Space flight</b>									
70	H, ♀, ♂	-	S	11 d	5	VL, I VL, II	= -18	= -47	= -23
107	R-F344, ♂	adult	S	10 d	10	SOL, I SOL, II	= =	-23 -12	= =
76	R-SD, ♂	adult	S	14 d	5	SOL, I SOL, II	-14* =	-46* =	-31* =
<b>Tenotomy</b>									
103	M-NMRI, ♀	-	T	14 d	-	EDL	=	-18	-

H: Human; R: Rat; M: Mouse; C: Cat; ♀: Female; ♂: Male; SD: rat strain Sprague-Dawley; W: rat strain Wistar; WI/HICK: rat strain WI/HICK; F344: rat strain Fischer 344; F344.BN: rat strain Fischer<sub>344</sub> x Brown Norway; B: Bed rest; DNV: denervation; SI: spinal cord injury; HLS: Hind-limb suspension; S: Space flight; T: Tenotomy; (N): number of animals; MN: myonuclear number; FCSA: fibre cross-sectional area; MD: myonuclear domain; Muscles: Diaph, Diaphragm; PL, Plantaris; EDL, Extensor digitorum longus; SM, Sternocleidomastoideus; SOL, Soleus; TA, Tibialis anterior; Gast, gastrocnemius; I, II(A,B) refer to muscle fibre type; All changes have been expressed as the change compared to a control normal muscles; =: no significant change between young and old animals; -: not reported; \*: change estimated from authors graph; ww: % change in wet weight muscle mass.

**Table 2.** Studies investigating the effect of atrophy on the myonuclear domain size.

cell depleted mice is realised by nuclei that are 'working flat out'. This may cause, admittedly speculative, nuclear dysfunction that over time may jeopardize the maintenance of the muscle fibres by attenuated protein turnover. It would therefore be interesting to know to what extent the quality of the muscle fibres of these hypertrophied muscles is affected over the life span of the animal. The addition of new myonuclei is a costly process and the fact that hypertrophy in normal organisms is associated with nuclear accretion is an indication of the importance of acquisition of new myonuclei for the maintenance of the increased muscle mass.

Overall, it appears that the nuclear domain is far from fixed, but rather increases during the development of hypertrophy (scenario in Figure 4C). However, there might be a 'ceiling' of the myonuclear domain size, or a maximal volume of cytoplasm that can be controlled by a single nucleus, beyond which hypertrophy can only proceed and be maintained for a prolonged time by addition of new myonuclei.

### Myonuclear domain and decreases in muscle size

Skeletal muscle atrophy is largely, if not solely, attributable to a decrease in fibre size. According to the concept of the myonuclear domain this should be associated with a proportional decrease in the number of myonuclei to maintain the myonuclear domain size. Below we will discuss what happens during muscle atrophy resulting from disuse and ageing, while ignoring the loss of fibres contributing to the atrophy during ageing (a nonexistent fibre will have no myonuclei).

Myonuclei can be eliminated by a process called apoptosis. Originally, this term was given to the types of cell deaths that were executed by intrinsic 'suicide' instructions and characterised by cell shrinkage and fragmentation of cell organelles that are ultimately digested by rapid phagocytosis<sup>64,65</sup>. During apoptosis, a cell nucleus can be degraded without the immediate destruction of the cell. In skeletal muscle, the ultimate event of nuclear apoptosis is the fragmentation of myonuclear DNA executed by so-called caspases. The activity of these enzymes is regulated by complex signalling pathways that involve the interaction of different pro- and anti-apoptotic factors<sup>66</sup>. Unlike other cell types, nuclear apoptosis in muscle fibres is very rare under normal physiological conditions<sup>67,68</sup>, but there is an increased expression of pro-apoptotic factors and number of apoptotic myonuclei following various atrophic stimuli<sup>66,69</sup>. The significance of nuclear apoptosis during atrophic conditions is, however, controversial.

#### Atrophy

The concept of a constant myonuclear domain size implies that muscle fibres loose myonuclei in proportion to (disuse-induced) atrophy. However, several observations do cast doubt on this concept in case of muscle atrophy. After 11 days of space flight, for instance, type II fibres in the vastus lateralis muscles from 2 out of 5 astronauts lost 18% of the myonuclei per mm fibre length, while the fibres atrophied by 47%<sup>70</sup>. This thus would result in a decreased, rather than constant, myonu-

clear domain size. Animal studies on the effect of disuse on the myonuclear number have generated some equivocal results (overview given in Table 2). In some studies a 50-70% reduction of the FCSA was accompanied with a considerable decrease in the number of myonuclei<sup>52,71,72</sup>, whereas in other studies a similar magnitude of atrophy was not associated with any change in the myonuclear number<sup>14,73-75</sup>. Part of this discrepancy might be explicable by the different response of type I and type II fibres to disuse. In rat soleus muscle for instance, both myonuclear number and FCSA were reduced after 12-days spaceflight in type I but not in type II fibres<sup>76</sup>. This is not unequivocal, however, as in denervated gastrocnemius muscles type I, IIA and IIB fibres all atrophied to the same extent and at the same rate without loss of myonuclei<sup>14</sup>. Even in the studies that observed myonuclear loss, this was not proportional to the magnitude of atrophy, and hence myonuclear domain size decreases during atrophy (Table 2), even independent of fibre type<sup>14</sup>. The decrease in myonuclear domain size is not explicable by a decrease in fibre oxidative capacity as observed during e.g. denervation<sup>77</sup> which would have to be associated with an increased rather than decreased myonuclear domain size.

The maintenance of myonuclei may be an appropriate strategy as the breakdown of myonuclei is an energy requiring process. Maybe even more important is that the muscle is 'ready' to respond to stimuli that induce hypertrophy. Newly acquired myonuclei during hypertrophy in mice muscle are not lost after subsequent 3 months of denervation<sup>78</sup> and this might provide the muscle with a 'memory' for later re-growth. These and other observations, such as satellite cell proliferation<sup>14,79-81</sup>, increased RNA and ribosomal concentration<sup>14,82</sup> and higher capillary density<sup>77</sup>, during the early stages of (denervation-induced) atrophy suggest that while proteins may be broken down rapidly the machinery and structures required to rapidly regain muscle mass are at least to some extent preserved. This machinery may also be required in the initial stages of atrophy to cope with the dramatic changes in gene expression<sup>83</sup>, and synthesis of enzymes and proteins involved in protein breakdown. This has indeed been observed after denervation where the expression of atrogens is transiently elevated 3-7 days after denervation<sup>84-86</sup> coinciding with the period of most dramatic atrophy<sup>14,77</sup>. During long-term atrophy, such as induced by denervation, the muscle regenerative capacity will ultimately be negatively affected<sup>87</sup>. These observations highlight a 'window of opportunity' where interventions to maintain muscle mass during hospitalisation and spaceflight are most effective early after the onset of disuse atrophy and may lose some of the effectiveness over time.

#### Ageing

The primary determinant of the age-related muscle weakening is the loss of muscle mass, also referred to as 'sarcopaenia' (see for review<sup>88</sup>). The process of sarcopaenia starts to manifest itself at the age of 60 and is the consequence of both a loss of muscle fibres and fibre atrophy<sup>89</sup>. If the concept of a constant myonuclear domain size would also apply to the ageing muscle, the age-related atrophy would be associated with a proportional reduction

Reference	Species	Age young (N)	Age old (N)	Muscle	change MN (%)	change FCSA (%)	change MD (%)
<b>Increase in MN</b>							
91	H, ♀	23±3 y (14)	76±4 y (14)	VL	19	-	-
	H, ♂	26±3 y (15)	74±4 y (13)	VL	19	-	-
92	H, ♂	20±1 y (8)	76±1 y (8)	VL, II	13	-27	-31
93	R-WI/Hick	4 mo. (-)	32 mo.	LA	39	-54	-80
13	R-F344	5 mo. (6)	24 mo. (8)	SOL, I	33	=	-24
				SOL, IIA	65	=	-34
14	R-W	5 mo. (15)	25 mo. (10)	Gast	36	37	=
99	H, ♂	27±2 (5)	82±3 (9)	VL, I	23	23	=
	H, ♀	28±2 (4)	84±8 (8)	VL, I	38	38	=
				VL, IIA	44*	-15	-41
<b>No change in MN</b>							
99	H, ♂	27±2 (5)	82±3 (9)	VL, IIA	=	-31	-33
41	H, ♀ ♂	22 (6) & 46 y (6)	65.1 y (6)	Mixed	=	=	-
94	H, ♀ ♂	24±4 y (4)	69±7 y (7)	Unknown	=	=	-
54	H, ♀	27.9±1.1 y (13)	62.8±1.0 y (13)	VL	=	-18	=
	H, ♀	26.1±1.4 y (13)	64.5±1.1 y (13)	VL	=	=	=
95	H, ♂	22.5±5.8 y (7)	65.0±6.0 y (8)	VL	=	-24	=
96	R-BN, ♂	5.5 mo (5)	27 mo (5)	TA	=	-8	=
97	R-F344.BN, ♂	6 mo (6)	32 mo (6)	SOL	=	-27	-29
13	R-F344	5 mo (6)	24 mo (8)	PL	=	=	=
				I,IIA, IIB/D	=	=	=
33	R-W	5 mo (12)	25 mo (10)	PL	=	=	=
<b>Decrease in MN</b>							
28	M	12 mo (-)	26-29 mo	TA	-20*	-33	=
90	M, ♀	14 mo (-)	23 mo	EDL	-20	↓	=
				SOL	-16	↓	=

H: Human; R: Rat; ♀: Female; ♂: Male; (N): number of participants / animals; RT: Resistance training; MN: myonuclear number; FCSA: fibre cross-sectional area; MD: myonuclear domain; Muscles: VL: vastus lateralis; PL: Plantaris; EDL: Extensor digitorum longus. All changes have been expressed as change in old compared to young muscles; =: no significant change between young and old animals; \*:change estimated from authors graph.

**Table 3.** Studies on the impact of ageing on the myonuclear domain size.

of the myonuclear number. Studies that have assessed the effect of ageing on the number of myonuclei are somewhat contradictory (see for an overview Table 3). The only two reports of a decrease in the number of myonuclei per unit muscle fibre length in old compared to young muscles were in mice<sup>28,90</sup>, while in human, rat and bird skeletal muscles, the number of myonuclei remained unchanged or even increased during ageing. It is not clear what causes these discrepancies, but the two studies that reported an age-related decrease in myonuclear number<sup>28,90</sup> analysed isolated single fibres, whereas in all other studies myonuclear number was determined from muscle cross-sections. However, even studies using the ‘cross-sectional’ approach have come to contradictory results with both an increase<sup>13,14,33,91-93</sup> and no change<sup>13,41,54,94-97</sup> in myonuclear number during ageing having been reported. These discrepancies may be more apparent than real and when one considers also the changes in fibre size most of the discrepancies are readily explicable. For instance, in the four studies that did not observe any change in the number of myonuclei per muscle fibre during ageing there was also no or

only a small change in the FCSA. Only in old women, a subgroup in the study by Petrella and colleagues<sup>54</sup>, there was atrophy without a significant reduction in myonuclear number. In rat gastrocnemius muscle there may have been a loss of fibres between the age of 5 and 25 months which was compensated by an increase in size of the remaining fibres<sup>14</sup>. This increase in fibre size is accompanied with a proportional increase in the number of myonuclei, thus maintaining the myonuclear domain size<sup>14</sup>, also in the plantaris muscle<sup>33</sup>. It thus seems that despite loss of muscle fibres during ageing, the relationship between fibre size and myonuclear number is maintained.

Another factor to consider is the absence of age-related muscle atrophy in some studies suggesting that ageing had not yet manifested in the muscles from the ‘old’ participants. In fact, several studies indicate that the age-related reduction in muscle volume and/or function occur mainly after the age of 70 (see for review<sup>88</sup>) and the mean age of the ‘old’ participants recruited in several studies<sup>41,54,94,95</sup> was below the age of 70 years. Similarly, in two<sup>96,97</sup> out of the three studies that reported



no change in the number of myonuclei per muscle fibre for the aged rat muscle, the age of the 'old' rats was still 4-5 months below the mean life expectancy of their strain and not really old animals<sup>98</sup>.

At very old age (i.e. >70% of the maximal life expectancy) the nuclear domain size may decrease, something that has indeed been observed in muscles from very old (32-month-old) rats<sup>93</sup>. Although in humans an increased number of myonuclei per fibre have been observed at advanced age<sup>91</sup>, this did not necessarily result in a decreased myonuclear domain size<sup>99</sup>. What is interesting, however, is that the distribution of myonuclei that is thought to be such that it minimizes diffusion distances between nuclei<sup>27</sup>, becomes more heterogeneous during ageing<sup>90,99</sup> and may impair local protein turnover.

Overall, the pattern emerges that up to a certain age the number of myonuclei per muscle fibre are not substantially affected by ageing even when muscle fibre atrophy has started. Further it seems that during ageing the number of myonuclei per muscle fibre may even increase. For humans, this may be after 70 years of age, while in rats this age may (somewhat) depend on the strain. As a result of the atrophy and increase in myonuclear number, myonuclear domain size may decrease at advanced age.

## Concluding remarks

The short answer to the question addressed in this review is that the myonuclear domain size is not fixed. Although one might then suggest abandoning the concept of a constant myonuclear domain entirely, this is too radical as in the normal situation a relationship between fibre size and myonuclear number does exist. It is only during maturational growth, ageing and when the muscle adapts to altered functional demands that deviations occur. Deviations might be understood when one realises that: 1) addition and removal of myonuclei is an expensive process and 2) a nucleus needs a reserve capacity to be able to respond to sudden changes in transcriptional demands and 3) during hypertrophy it must be able to bridge the period between activation and incorporation of satellite cells into the myofibre. The preservation of myonuclei during atrophy may be an excellent strategy to save energy and at the same time have the muscle 'ready' for subsequent recovery of muscle mass. Another factor that might be of importance, as we suggested before<sup>100</sup>, is the distribution of myonuclei within the muscle fibre. While a lot of attention has been given to the size of the myonuclear domain in terms of cytoplasmic volume, more attention may need to be given to the number per fibre perimeter and distribution of the myonuclei over the perimeter of the fibre, given that during for instance maturational growth the number of myonuclei per fibre radius remains constant<sup>41</sup>.

## References

1. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. *Int J Biochem Cell Biol* 2005;37:1974-84.
2. van Wessel T, de Haan A, van der Laarse WJ, Jaspers RT. The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism? *Eur J Appl Physiol* 2010;110:665-94.
3. Kandarian SC, Jackman RW. Intracellular signaling during skeletal muscle atrophy. *Muscle & Nerve* 2006;33:155-165.
4. Reid MB. Response of the ubiquitin-proteasome pathway to changes in muscle activity. *Am J Physiol Regul Integr Comp Physiol* 2005;288:R1423-31.
5. Powers SK, Kavazis AN, McClung JM. Oxidative stress and disuse muscle atrophy. *J Appl Physiol* 2007;102:2389-97.
6. Nader GA, Hornberger TA, Esser KA. Translational control: implications for skeletal muscle hypertrophy. *Clin Orthop Relat Res* 2002;S178-87.
7. Sugden PH, Fuller SJ. Regulation of protein turnover in skeletal and cardiac muscle. *Biochem J* 1991;273(Pt.1):21-37.
8. Kawano F, Takeno Y, Nakai N, Higo Y, Terada M, Ohira T, Nonaka I, Ohira Y. Essential role of satellite cells in the growth of rat soleus muscle fibers. *Am J Physiol Cell Physiol* 2008;295:C458-67.
9. Zammit PS, Partridge TA, Yablonka-Reuveni Z. The skeletal muscle satellite cell: the stem cell that came in from the cold. *J Histochem Cytochem* 2006;54:1177-91.
10. Schmalbruch H, Hellhammer U. The number of nuclei in adult rat muscles with special reference to satellite cells. *Anat Rec* 1977;189:169-75.
11. Schmalbruch H, Lewis DM. Dynamics of nuclei of muscle fibers and connective tissue cells in normal and denervated rat muscles. *Muscle & Nerve* 2000;23:617-26.
12. Kelly AM. Satellite cells and myofiber growth in the rat soleus and extensor digitorum longus muscles. *Dev Biol* 1978;65:1-10.
13. Brooks NE, Schuenke MD, Hikida RS. Ageing influences myonuclear domain size differently in fast and slow skeletal muscle of rats. *Acta Physiol (Oxf)* 2009;197:55-63.
14. van der Meer SF, Jaspers RT, Jones DA, Degens H. Time-course of changes in the myonuclear domain during denervation in young-adult and old rat gastrocnemius muscle. *Muscle & Nerve* 2011;43:212-22.
15. Jaspers RT, Feenstra HM, van Beek-Harmsen BJ, Huijling PA, van der Laarse WJ. Differential effects of muscle fibre length and insulin on muscle-specific mRNA content in isolated mature muscle fibres during long-term culture. *Cell Tissue Res* 2006;326:795-808.
16. Strasburger E, Ueber die Wirkungssphäre der Kerne und die Zellgrösse. 1893.
17. Gregory TR. Coincidence, coevolution, or causation? DNA content, cell size, and the C-value enigma. *Biol Rev Camb Philos Soc* 2001;76:65-101.
18. Moss FP. The relationship between the dimensions of the fibres and the number of nuclei during normal growth of skeletal muscle in the domestic fowl. *Am J Anat* 1968;122:555-63.
19. Moss FP. The relationship between the dimensions of the

- fibres and the number of nuclei during restricted growth, degrowth and compensatory growth of skeletal muscle. *Am J Anat* 1968;122:565-71.
20. Cheek DB. The control of cell mass and replication. The DNA unit - a personal 20-year study. *Early Hum Dev* 1985;12:211-39.
21. Landing BH, Dixon LG, Wells TR. Studies on isolated human skeletal muscle fibers, including a proposed pattern of nuclear distribution and a concept of nuclear territories. *Hum Pathol* 1974;5:441-61.
22. Edgerton VR, Roy RR. Regulation of skeletal muscle fiber size, shape and function. *J Biomech* 1991;24(Suppl.1):123-33.
23. Hall ZW, Ralston E. Nuclear domains in muscle cells. *Cell* 1989;59:771-2.
24. Merlie JP, Sanes JR. Concentration of acetylcholine receptor mRNA in synaptic regions of adult muscle fibres. *Nature* 1985;317:66-8.
25. Pavlath GK, Rich K, Webster SG, Blau HM. Localization of muscle gene products in nuclear domains. *Nature* 1989;337:570-3.
26. Ralston E, Hall ZW. Restricted distribution of mRNA produced from a single nucleus in hybrid myotubes. *J Cell Biol* 1992;119:1063-8.
27. Bruusgaard JC, Liestol K, Ekmark M, Kollstad K, Gundersen K. Number and spatial distribution of nuclei in the muscle fibres of normal mice studied *in vivo*. *J Physiol* 2003;551:467-78.
28. Brack AS, Bildsoe H, Hughes SM. Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. *J Cell Sci* 2005;118:4813-21.
29. Roy RR, Monke SR, Allen DL, Edgerton VR. Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers. *J Appl Physiol* 1999;87:634-42.
30. Kadi F, Eriksson A, Holmner S, Butler-Browne GS, Thornell LE. Cellular adaptation of the trapezius muscle in strength-trained athletes. *Histochem Cell Biol* 1999;111:189-95.
31. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. *Am J Physiol Endocrinol Metab* 2002;283:E154-64.
32. Tseng BS, Kasper CE, Edgerton VR. Cytoplasm-to-myonucleus ratios and succinate dehydrogenase activities in adult rat slow and fast muscle fibers. *Cell Tissue Res* 1994;275:39-49.
33. van der Meer SF, Jaspers RT, Jones DA, Degens H. The time course of myonuclear accretion during hypertrophy in young adult and older rat plantaris muscle. *Ann Anat* 2011;193:56-63.
34. Lewis SE, Kelly FJ, Goldspink DF. Pre- and post-natal growth and protein turnover in smooth muscle, heart and slow- and fast-twitch skeletal muscles of the rat. *Biochem J* 1984;217:517-26.
35. Mauro A. Satellite cell of skeletal muscle fibers. *J Biophys Biochem Cytol* 1961;9:493-5.
36. Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? *J Cell Biol* 2004;166:347-57.
37. Gollnick PD, Timson BF, Moore RL, Riedy M. Muscular enlargement and number of fibers in skeletal muscles of rats. *J Appl Physiol* 1981;50:936-43.
38. Malina RM. Growth of muscle tissue and muscle mass, in *Human growth; Volume 2: Postnatal growth*, F. Falkner, Tanner, J.M., Editor. 1978, Ballière Tindall: London. p. 273-294.
39. Degens H, Deveci D, Botto-van Bemden A, Hoofd LJ, Egginton S. Maintenance of heterogeneity of capillary spacing is essential for adequate oxygenation in the soleus muscle of the growing rat. *Microcirculation* 2006;13:467-76.
40. Oertel G. Morphometric analysis of normal skeletal muscles in infancy, childhood and adolescence. An autopsy study. *J Neurol Sci* 1988;88:303-13.
41. Vassilopoulos D, Lumb EM, Emery AE. Karyometric changes in human muscle with age. *Eur Neurol* 1977;16:31-4.
42. White RB, Bierinx AS, Gnocchi VF, Zammit PS. Dynamics of muscle fibre growth during postnatal mouse development. *BMC Dev Biol* 2010;10:21.
43. O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. *In vivo* measurements of muscle specific tension in adults and children. *Exp Physiol* 2010;95:202-10.
44. Enesco M, Puddy D. Increase in the Number of Nuclei and Weight in Skeletal Muscle of Rats of Various Ages. *Am J Anat* 1964;114:235-44.
45. Ohira Y, Tanaka T, Yoshinaga T, Kawano F, Nomura T, Nonaka I, Allen DL, Roy RR, Edgerton VR. Ontogenetic, gravity-dependent development of rat soleus muscle. *Am J Physiol Cell Physiol* 2001;280:C1008-16.
46. Mantilla CB, Sill RV, Aravamudan B, Zhan WZ, Sieck GC. Developmental effects on myonuclear domain size of rat diaphragm fibers. *J Appl Physiol* 2008;104:787-94.
47. Moss FP, Leblond CP. Nature of dividing nuclei in skeletal muscle of growing rats. *J Cell Biol* 1970;44:459-62.
48. Mozdziaik PE, Pulvermacher PM, Schultz E. Unloading of juvenile muscle results in a reduced muscle size 9 wk after reloading. *J Appl Physiol* 2000;88:158-64.
49. O'Connor RS, Pavlath GK, McCarthy JJ, Esser KA. Point: Counterpoint Satellite cell addition is / is not obligatory for skeletal muscle hypertrophy. *J Appl Physiol* 2007;103(3):1107.
50. McCarthy JJ, Esser KA. Counterpoint: Satellite cell addition is not obligatory for skeletal muscle hypertrophy. *Journal of applied physiology* 2007;103:1100-2; discussion 1102-3.
51. Adams GR, Caiozzo VJ, Haddad F, Baldwin KM. Cellular and molecular responses to increased skeletal muscle

- loading after irradiation. *Am J Physiol Cell Physiol* 2002; 283:C1182-95.
52. Kawano F, Matsuoka Y, Oke Y, Higo Y, Terada M, Wang XD, Nakai N, Fukuda H, Imajoh-Ohmi S, Ohira Y. Role(s) of nucleoli and phosphorylation of ribosomal protein S6 and/or HSP27 in the regulation of muscle mass. *Am J Physiol Cell Physiol* 2007;293:C35-44.
  53. Allen DL, Monke SR, Talmadge RJ, Roy RR, Edgerton VR. Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal muscle fibers. *J Appl Physiol* 1995;78:1969-76.
  54. Petrella JK, Kim JS, Cross JM, Kosek DJ, Bamman MM. Efficacy of myonuclear addition may explain differential myofiber growth among resistance-trained young and older men and women. *Am J Physiol Endocrinol Metab* 2006;291:E937-46.
  55. Lowe DA, Alway SE. Stretch-induced myogenin, MyoD, and MRF4 expression and acute hypertrophy in quail slow-tonic muscle are not dependent upon satellite cell proliferation. *Cell Tissue Res* 1999;296:531-9.
  56. Rosenblatt JD, Parry DJ. Adaptation of rat extensor digitorum longus muscle to gamma irradiation and overload. *Pflügers Arch* 1993;423:255-64.
  57. Rosenblatt JD, Yong D, Parry DJ. Satellite cell activity is required for hypertrophy of overloaded adult rat muscle. *Muscle & Nerve* 1994;17:608-13.
  58. Phelan JN, Gonyea WJ. Effect of radiation on satellite cell activity and protein expression in overloaded mammalian skeletal muscle. *Anat Rec* 1997;247:179-88.
  59. Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen JL, Christensen LR, Andersen JL. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. *J Physiol* 2004;558:1005-12.
  60. Snow MH. Satellite cell response in rat soleus muscle undergoing hypertrophy due to surgical ablation of synergists. *Anat Rec* 1990;227:437-46.
  61. Liu JX, Hoglund AS, Karlsson P, Lindblad J, Qaisar R, Aare S, Bengtsson E, Larsson L. Myonuclear domain size and myosin isoform expression in muscle fibres from mammals representing a 100,000-fold difference in body size. *Exp Physiol* 2009;94:117-29.
  62. Bodine SC. In response to Point:Counterpoint: "Satellite cell addition is/is not obligatory for skeletal muscle hypertrophy". *J Appl Physiol* 2007;103:1105-6.
  63. McCarthy JJ, Mula J, Miyazaki M, Erfani R, Garrison K, Farooqui AB, Srikuea R, Lawson BA, Grimes B, Keller C, Van Zant G, Campbell KS, Esser KA, Dupont-Versteegden EE, Peterson CA. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. *Development* 2011;138:3657-66.
  64. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. *Ann N Y Acad Sci* 2003;1010:1-8.
  65. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972;26:239-57.
  66. Marzetti E, Hwang JC, Lees HA, Wohlgemuth SE, Dupont-Versteegden EE, Carter CS, Bernabei R, Leeuwenburgh C. Mitochondrial death effectors: Relevance to sarcopenia and disuse muscle atrophy. *Biochim Biophys Acta* 2010;1800(3):235-44.
  67. Adhihetty PJ, O'Leary MF, Chabi B, Wicks KL, Hood DA. Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle. *J Appl Physiol* 2007; 102:1143-51.
  68. Dupont-Versteegden EE, Murphy RJ, Houle JD, Gurley CM, Peterson CA. Activated satellite cells fail to restore myonuclear number in spinal cord transected and exercised rats. *Am J Physiol* 1999;277:C589-97.
  69. Siu PM, Alway SE. Response and adaptation of skeletal muscle to denervation stress: the role of apoptosis in muscle loss. *Front Biosci* 2009;14:432-52.
  70. Day MK, Allen DL, Mohajerani L, Greenisen MC, Roy RR, Edgerton VR. Adaptations of human skeletal muscle fibers to spaceflight. *J Gravit Physiol* 1995;2:P47-50.
  71. Zhong H, Roy RR, Siengthai B, Edgerton VR. Effects of inactivity on fiber size and myonuclear number in rat soleus muscle. *J Appl Physiol* 2005;99:1494-9.
  72. Allen DL, Linderman JK, Roy RR, Grindeland RE, Mukku V, Edgerton VR. Growth hormone/IGF-I and/or resistive exercise maintains myonuclear number in hindlimb unweighted muscles. *J Appl Physiol* 1997;83:1857-61.
  73. Kasper CE, Xun L. Cytoplasm-to-myonucleus ratios in plantaris and soleus muscle fibres following hindlimb suspension. *J Muscle Res Cell Motil* 1996;17:603-10.
  74. Aravamudan B, Mantilla CB, Zhan WZ, Sieck GC. Denervation effects on myonuclear domain size of rat diaphragm fibers. *J Appl Physiol* 2006;100:1617-22.
  75. Wada KI, Takahashi H, Katsuta S, Soya H. No decrease in myonuclear number after long-term denervation in mature mice. *Am J Physiol Cell Physiol* 2002;283:C484-8.
  76. Allen DL, Yasui W, Tanaka T, Ohira Y, Nagaoka S, Sekiguchi C, Hinds WE, Roy RR, Edgerton VR. Myonuclear number and myosin heavy chain expression in rat soleus single muscle fibers after spaceflight. *J Appl Physiol* 1996;81:145-51.
  77. Degens H, Kosar SN, Hopman MT, de Haan A. The time course of denervation-induced changes is similar in soleus muscles of adult and old rats. *Appl Physiol Nutr Metab* 2008;33:299-308.
  78. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. *Proc Natl Acad Sci U S A* 2010;107:15111-6.
  79. Dedkov EI, Borisov AB, Wernig A, Carlson BM. Aging of skeletal muscle does not affect the response of satellite cells to denervation. *J Histochem Cytochem* 2003; 51:853-63.
  80. Kuschel R, Yablonka-Reuveni Z, Bornemann A. Satellite cells on isolated myofibers from normal and denervated adult rat muscle. *J Histochem Cytochem* 1999;47:1375-84.
  81. Ontell M. Muscle satellite cells: a validated technique for



- light microscopic identification and a quantitative study of changes in their population following denervation. *Anat Rec* 1974;178:211-27.
82. Ionasescu V, Lewis R, Schottelius B. Neurogenic control of muscle ribosomal protein synthesis. *Acta Neurol Scand* 1975;51:253-67.
83. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. *J Physiol* 2003;551:33-48.
84. Beehler BC, Sleph PG, Benmassaoud L, Grover GJ. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. *Exp Biol Med (Maywood)* 2006;231:335-41.
85. Medina R, Wing SS, Goldberg AL. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. *Biochem J* 1995; 307(Pt.3):631-7.
86. Sackcheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. *Faseb J* 2007;21:140-55.
87. Dedkov EI, Kostrominova TY, Borisov AB, Carlson BM. Reparative myogenesis in long-term denervated skeletal muscles of adult rats results in a reduction of the satellite cell population. *Anat Rec* 2001;263:139-54.
88. Doherty TJ. Invited review: Aging and sarcopenia. *J Appl Physiol* 2003;95:1717-27.
89. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. *J Neurol Sci* 1988;84:275-94.
90. Bruusgaard JC, Liestol K, Gundersen K. Distribution of myonuclei and microtubules in live muscle fibers of young, middle-aged, and old mice. *J Appl Physiol* 2006; 100:2024-30.
91. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. *Muscle & Nerve* 2004;29:120-7.
92. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. *Am J Physiol Endocrinol Metab* 2007;292:E151-7.
93. Nnodim JO. Satellite cell numbers in senile rat levator ani muscle. *Mech Ageing Dev* 2000;112:99-111.
94. Manta P, Vassilopoulos D, Spengos M. Nucleo-cytoplasmic ratio in ageing skeletal muscle. *Eur Arch Psychiatry Neurol Sci* 1987;236:235-6.
95. Hikida RS, Walsh S, Barylski N, Campos G, Hagerman FC, Staron RS. Is hypertrophy limited in elderly muscle fibers? A comparison of elderly and young strength-trained men. *Basic Applied Myology* 1998;8:419-27.
96. Putman CT, Sultan KR, Wassmer T, Bamford JA, Skorejanc D, Pette D. Fiber-type transitions and satellite cell activation in low-frequency-stimulated muscles of young and aging rats. *J Gerontol A Biol Sci Med Sci* 2001; 56:B510-9.
97. Gallegly JC, Turesky NA, Strotman BA, Gurley CM, Peterson CA, Dupont-Versteegden EE. Satellite cell regulation of muscle mass is altered at old age. *J Appl Physiol* 2004;97:1082-90.
98. Lipman RD, Chrisp CE, Hazzard DG, Bronson RT. Pathologic characterization of brown Norway, brown Norway x Fischer 344, and Fischer 344 x brown Norway rats with relation to age. *J Gerontol A Biol Sci Med Sci* 1996;51:B54-9.
99. Cristea A, Qaisar R, Edlund PK, Lindblad J, Bengtsson E, Larsson L. Effects of aging and gender on the spatial organization of nuclei in single human skeletal muscle cells. *Aging Cell* 2010;9:685-97.
100. Degens H, Rittweger J. What is new in musculoskeletal interactions? Muscle oxygenation, myonuclear domain, acupuncture, titin and phosphate. *J Musculoskelet Neuronal Interact* 2010;10:245-8.
101. Ohira Y, Yoshinaga T, Ohara M, Nonaka I, Yoshioka T, Yamashita-Goto K, Shenkman BS, Kozlovskaya IB, Roy RR, Edgerton VR. Myonuclear domain and myosin phenotype in human soleus after bed rest with or without loading. *J Appl Physiol* 1999;87:1776-85.
102. Milanic T, Kunstelj A, Mars T, Grubic Z. Morphometric characteristics of myonuclear distribution in the normal and denervated fast rat muscle fiber. *Chem Biol Interact* 1999;119-120:321-6.
103. Bruusgaard JC, Gundersen K. *In vivo* time-lapse microscopy reveals no loss of murine myonuclei during weeks of muscle atrophy. *J Clin Invest* 2008;118:1450-7.
104. Viguie CA, Lu DX, Huang SK, Rengen H, Carlson BM. Quantitative study of the effects of long-term denervation on the extensor digitorum longus muscle of the rat. *Anat Rec* 1997;248:346-54.
105. Leeuwenburgh C, Gurley CM, Strotman BA, Dupont-Versteegden EE. Age-related differences in apoptosis with disuse atrophy in soleus muscle. *Am J Physiol Regul Integr Comp Physiol* 2005;288:R1288-96.
106. Matsuba Y, Goto K, Morioka S, Naito T, Akema T, Hashimoto N, Sugiura T, Ohira Y, Beppu M, Yoshioka T. Gravitational unloading inhibits the regenerative potential of atrophied soleus muscle in mice. *Acta Physiol (Oxf)* 2009;196:329-39.
107. Hikida RS, Van Nostran S, Murray JD, Staron RS, Gordon SE, Kraemer WJ. Myonuclear loss in atrophied soleus muscle fibers. *Anat Rec* 1997;247:350-4.